Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H15N2O6S2.Na |
| Molecular Weight | 406.409 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C([O-])=O)C3=CSC=C3)C(O)=O
InChI
InChIKey=PBVBBUWVRCCZHI-GHRKWLBTSA-M
InChI=1S/C15H16N2O6S2.Na/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6;/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23);/q;+1/p-1/t7-,8-,9+,12-;/m1./s1
Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | TICAR Approved UseUnknown Launch Date1976 |
|||
| Curative | TICAR Approved UseUnknown Launch Date1976 |
|||
| Curative | TICAR Approved UseUnknown Launch Date1976 |
|||
| Curative | TICAR Approved UseUnknown Launch Date1976 |
|||
| Curative | TICAR Approved UseUnknown Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
324 μg/mL |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
431.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
621.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
576.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
485 μg × h/mL |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
538 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
890 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
747 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
339 μg × h/mL |
50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
76 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140806/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
TICARCILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.1 h |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
80.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
84.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
74.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/ |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
TICARCILLIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1 h |
50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
55% |
3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM |
TICARCILLIN serum | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: Page: p.90 |
unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: Page: p.90 |
Disc. AE: Rash, Nausea... Other AEs: Elevated liver enzymes, Eosinophilia... AEs leading to discontinuation/dose reduction: Rash (grade 1, 2.7%) Other AEs:Nausea (grade 2, 2.7%) Elevated liver enzymes Sources: Page: p.90Eosinophilia |
80 mg/kg single, intravenous Highest studied dose Dose: 80 mg/kg Route: intravenous Route: single Dose: 80 mg/kg Sources: Page: p.360 |
healthy, 22-26 n = 8 Health Status: healthy Age Group: 22-26 Sex: M+F Population Size: 8 Sources: Page: p.360 |
|
3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Other AEs: Convulsions... Other AEs: Convulsions Sources: Page: p.1 |
3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Other AEs: Hypersensitivity reaction, Diarrhea, Clostridium difficile... Other AEs: Hypersensitivity reaction (grade 3-5) Sources: Page: p.1Diarrhea, Clostridium difficile |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Elevated liver enzymes | 3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: Page: p.90 |
unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: Page: p.90 |
|
| Eosinophilia | 3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: Page: p.90 |
unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: Page: p.90 |
|
| Rash | grade 1, 2.7% Disc. AE |
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: Page: p.90 |
unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: Page: p.90 |
| Nausea | grade 2, 2.7% Disc. AE |
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: Page: p.90 |
unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: Page: p.90 |
| Convulsions | 3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
|
| Diarrhea, Clostridium difficile | 3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
|
| Hypersensitivity reaction | grade 3-5 | 3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The relationships and susceptibilities of some industrial, laboratory and clinical isolates of Pseudomonas aeruginosa to some antibiotics and biocides. | 2001 Dec |
|
| Timentin overdose. "No admittance" to the pharmacy? | 2002 Apr |
|
| Antibiotic-associated maculopapular reaction. | 2002 Dec |
|
| Occurrence of Salmonella enterica serotype typhimurium DT104A in retail ground beef. | 2002 Feb |
|
| Clinical evaluation of the Vitek automated system with cards GNS 122 and 127 and VTK-R07.01 software for antimicrobial susceptibility testing of Pseudomonas aeruginosa. | 2002 Jan |
|
| Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). | 2002 Jul |
|
| Growth of cell-wall-deficient variants of Enterobacter cloacae facilitates beta-lactamase derepressed mutants. | 2002 May |
|
| beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. | 2002 Nov |
|
| Efficiency of procedures for induction and cultivation of Pseudomonas syringae pv. pisi L-form. | 2003 |
|
| Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma. | 2003 Apr |
|
| Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea. | 2003 Apr |
|
| Antimicrobial susceptibility and synergistic activity of meropenem against Gram-negative non-fermentative bacteria isolated from cystic fibrosis patients. | 2003 Dec |
|
| Late bacterial keratitis after implantation of intrastromal corneal ring segments. | 2003 Feb |
|
| Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. | 2003 Feb |
|
| Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii. | 2003 Jul |
|
| Beta-lactamase production in Prevotella and in vitro susceptibilities to selected beta-lactam antibiotics [corrected]. | 2003 Mar |
|
| [Antibiotic resistance of Acinetobacter baumannii isolates: data from Ibni Sina Hospital for the year 2002]. | 2003 Oct |
|
| Haemorrhagic cystitis with ticarcillin: risk factors include cystic fibrosis. | 2003 Oct |
|
| Natural antibiotic susceptibility of Ewingella americana strains. | 2003 Oct |
|
| Natural antimicrobial susceptibilities and biochemical profiles of Yersinia enterocolitica-like strains: Y. frederiksenii, Y. intermedia, Y. kristensenii and Y. rohdei. | 2003 Sep 22 |
|
| [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens]. | 2004 |
|
| [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics]. | 2004 |
|
| Detection of ticarcillin-clavulonic acid susceptibility with microdilution method in Citrobacter, Hafnia, Proteus and some gram negative bacteria. | 2004 |
|
| [Management of ENT diseases complications using ticarcillin clavulanate]. | 2004 |
|
| An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. | 2004 Apr |
|
| Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases. | 2004 Apr |
|
| A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. | 2004 Aug |
|
| Detection and assay of beta-lactamases in clinical and non-clinical strains of Yersinia enterocolitica biovar 1A. | 2004 Aug |
|
| The value of a CT-guided fine needle aspirate in infants with lung abscess. | 2004 Aug |
|
| Antibiotic susceptibility patterns among respiratory isolates of Gram-negative bacilli in a Turkish university hospital. | 2004 Aug 22 |
|
| [Pseudomonas aeruginosa: a multicentric study of antibiotic resistance (1999-2000)]. | 2004 Dec |
|
| [Infectious cellulitis and Shewanella alga septicemia in an immunocompetent patient]. | 2004 Dec |
|
| Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. | 2004 Dec |
|
| Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. | 2004 Feb |
|
| [Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area]. | 2004 Jan |
|
| Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing beta-lactam resistance. | 2004 Jan 15 |
|
| [A 4-year study of Pseudomonas aeruginosa susceptibility to antibiotics (1998-2001) in northern Lebanon]. | 2004 Jul |
|
| Clinical significance of Roseomonas species isolated from catheter and blood samples: analysis of 36 cases in patients with cancer. | 2004 Jun 1 |
|
| Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice. | 2004 Mar |
|
| [Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem]. | 2004 May |
|
| Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. | 2004 Sep |
|
| CTX-M beta-lactamase-producing Escherichia coli in long-term care facilities, France. | 2004 Sep |
|
| Resistance to beta-lactam antibiotics in Aeromonas hydrophila isolated from rainbow trout (Oncorhynchus mykiss). | 2004 Sep |
|
| Antimicrobial resistance of selected Salmonella isolates from food animals and food in Alberta. | 2005 Feb |
|
| Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas. | 2005 Jan |
|
| Antimicrobial susceptibility of bifidobacteria. | 2005 Jan |
|
| Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia albertii and Hafnia alvei strains. | 2005 Mar |
|
| Inquilinus limosus in patients with cystic fibrosis, Germany. | 2005 Mar |
|
| Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. | 2005 Mar |
|
| Acinetobacter baumanii folliculitis in a patient with AIDS. | 2005 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ticar.html
Bacterial septicemia: 200 to 300 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours.
Respiratory tract infections: (The usual dose is 3 grams given every 4 hours [18 grams/day] or 4 grams given every 6 hours [16 grams/day] depending on weight and the severity of the infection.)
Urinary tract infections: Complicated: 150 to 200 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. (Usual recommended dosage for average [70 kg] adults: 3 grams q.i.d.)
Uncomplicated: 1 gram I.M. or direct I.V. every 6 hours.
Route of Administration:
Other
A total of 632 clinical bacterial isolates were tested for susceptibility to twofold dilutions of ticarcillin alone and in combination with 1, 2, and 4 micrograms of clavulanic acid (CA) (Timentin) per ml by a reference microdilution method. With the addition of CA, ticarcillin MICs were reduced eightfold or greater with 54 of 59 (92%) strains of the family Enterobacteriaceae with ticarcillin MICs of greater than or equal to 64 micrograms/ml. Ticarcillin MICs for beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, and most Staphylococcus aureus were reduced to less than or equal to 0.5 micrograms/ml when CA was added.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
70691440
Created by
admin on Fri Dec 15 15:48:46 GMT 2023 , Edited by admin on Fri Dec 15 15:48:46 GMT 2023
|
PRIMARY | |||
|
SM6JM116PM
Created by
admin on Fri Dec 15 15:48:46 GMT 2023 , Edited by admin on Fri Dec 15 15:48:46 GMT 2023
|
PRIMARY | |||
|
74682-62-5
Created by
admin on Fri Dec 15 15:48:46 GMT 2023 , Edited by admin on Fri Dec 15 15:48:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
